Showing results (1951-1960 of 2,127) with videos related to

Sort By:
Pageof 213
Acta Neuropathologica Communications|April 27, 2021
Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's diseaseJong-Sung Park, Tae-In Kam, Saebom Lee, et al.
Chest|October 10, 2024
Gender Differences in Outcomes of Ambulatory and Hospitalized Patients With Obesity Hypoventilation SyndromeNathan C Nowalk, Babak Mokhlesi, Julie M Neborak, et al.
Trials|December 19, 2019
Effectiveness and cost-effectiveness of Improving clinicians' diagnostic and communication Skills on Antibiotic prescribing Appropriateness in patients with acute Cough in primary care in CATalonia (the ISAAC-CAT study): study protocol for a cluster randomised controlled trialRafa Ruiz, Ana Moragas, Marta Trapero-Bertran, et al.
The Journal of Clinical Investigation|July 12, 2008
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanismsZhi Gang Li, Paul Mathew, Jun Yang, et al.
Acta Neuropathologica|November 8, 2025
PolyGR-containing aggregates link with pathology and clinical features of Alzheimer's diseaseHuong T Phuong, Rodrigo F Tomas, Cemal Akmese, et al.
Molecular Cancer Therapeutics|June 23, 2021
PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate CancerCheng Wu, Shan Peng, Patrick G Pilié, et al.
Cancer|April 3, 2015
Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man studyRenata Pasqualini, Randall E Millikan, Dawn R Christianson, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Transcriptomic and protein analysis of human cortex reveals genes and pathways linked to NPTX2 disruption in Alzheimer's diseaseYuelin Lao, Mei-Fang Xiao, Shiyu Ji, et al.
BJU International|June 11, 2015
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillanceJohn W Davis, John F Ward, Curtis A Pettaway, et al.
BJU International|June 5, 2024
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlatesAndrew W Hahn, Ganiraju C Manyam, Brian F Chapin, et al.
Pageof 213